CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
暂无分享，去创建一个
W. Sellers | N. Socci | A. Viale | K. Manova | R. Levine | Ernesta Dammassa | N. Ebel | F. Hofmann | F. Rapaport | R. Hoffman | M. Murakami | A. Shih | O. Guryanova | M. Kleppe | T. Radimerski | P. Koppikar | R. Rampal | Jihae Ahn | C. Gaul | Vincent Romanet | F. Baffert | A. McKenney | D. Pankov | S. Meyer | M. Keller | Sophia Chiu | Ke Xu | R. O'reilly | K. Shank | E. Papalexi | B. Spitzer | Emeline Mandon | R. Andraos | Joëlle Rubert | A. Dölemeyer | Michael Zender | Melanie Heinlein | R. Weinberg | Franck Rapaport | Priya Koppikar | E. Mandon